SFZN Stock Analysis: Siegfried Holding | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 3.235m CHF | 12M Return: -11.6% | CH0014284498 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.04M
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Siegfried Holding AG (SFZN) is a Swiss-based contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients (APIs) and finished dosage forms for pharmaceutical clients worldwide. The company operates through two main segments: drug substances, which includes custom API manufacturing and a portfolio of non-exclusive APIs focused on therapeutic areas such as anesthetics, pain and addiction treatment, central nervous system and respiratory diseases, plus pharmaceutical-grade caffeine; and drug products, covering sterile fill-and-finish (vials, ampoules, cartridges, pre-filled syringes), ophthalmics, inhalation capsules, oral solid dosage forms (tablets and capsules), and viral vectors for cell and gene therapies. Founded in 1873 and headquartered in Zofingen, Switzerland, Siegfried offers a broad technology platform spanning chemistry, analytical services, formulation, containment, and cell and gene therapy capabilities.
Within the pharmaceutical CDMO sector, Siegfried serves as an outsourced manufacturing partner to both brand-name drug developers and generic drug producers, allowing clients to access specialized production capacity, regulatory expertise, and technical capabilities without building them in-house. The CDMO model typically involves long-term supply agreements and high regulatory barriers to entry, given the stringent good manufacturing practice (GMP) standards required by health authorities.
- Steriles fill-finish demand expands order pipeline and capacity utilization
- Cell and gene therapy capacity buildout adds high-margin growth vector
- API margin compression persists amid Asian generic competition
| Net Income: 171.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 64.57% < 20% (prev 47.78%; Δ 16.79% < -1%) |
| CFO/TA 0.07 > 3% & CFO 165.8m > Net Income 171.3m |
| Net Debt (820.0m) to EBITDA (313.2m): 2.62 < 3 |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.9m) vs 12m ago 2.02% < -2% |
| Gross Margin: 26.97% > 18% (prev 25.69%; Δ 1.27% > 0.5%) |
| Asset Turnover: 61.12% > 50% (prev 65.64%; Δ -4.51% > 0%) |
| Interest Coverage Ratio: 19.38 > 6 (EBIT TTM 210.9m / Interest Expense TTM 10.9m) |
| A: 0.36 (Total Current Assets 1.22b - Total Current Liabilities 353.1m) / Total Assets 2.42b |
| B: 0.44 (Retained Earnings 1.06b / Total Assets 2.42b) |
| C: 0.10 (EBIT TTM 210.9m / Avg Total Assets 2.19b) |
| D: 0.70 (Book Value of Equity 994.7m / Total Liabilities 1.42b) |
| Altman-Z'' = 5.16 = AAA |
| DSRI: 1.00 (Receivables 328.0m/317.0m, Revenue 1.34b/1.29b) |
| GMI: 0.95 (GM 25.69% / 26.97%) |
| AQI: 1.05 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 1.04 (Revenue 1.34b / 1.29b) |
| TATA: 0.00 (NI 171.3m - CFO 165.8m) / TA 2.42b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of August 29, 2026, the stock is trading at CHF 74.15 with a total of 157,656 shares traded. Over the past week, the price has changed by -7.60%, over one month by +1.78%, over three months by -9.57% and over the past year by -11.59%.
Current recommended Stop Loss: 68.40 (which is 7.8% or 2.3 ATR below the current price).
Siegfried Holding has no consensus analysts rating.
P/E Trailing = 18.9359
P/E Forward = 17.7936
P/S = 2.412
P/B = 3.2548
P/EG = 1.6642
Revenue TTM = 1.34b CHF
EBIT TTM = 210.9m CHF
EBITDA TTM = 313.2m CHF
Long Term Debt = 375.2m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 200.0m CHF (from shortTermDebt, last fiscal year)
Debt = 925.2m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = 820.0m CHF (calculated: Debt 925.2m - CCE 105.2m)
Enterprise Value = 4.06b CHF (3.24b + Debt 925.2m - CCE 105.2m)
Interest Coverage Ratio = 19.38 (Ebit TTM 210.9m / Interest Expense TTM 10.9m)
EV/FCF = -222.3x (Enterprise Value 4.06b / FCF TTM -18.2m)
FCF Yield = -0.45% (FCF TTM -18.2m / Enterprise Value 4.06b)
FCF Margin = -1.36% (FCF TTM -18.2m / Revenue TTM 1.34b)
Net Margin = 12.77% (Net Income TTM 171.3m / Revenue TTM 1.34b)
Gross Margin = 26.97% ((Revenue TTM 1.34b - Cost of Revenue TTM 979.6m) / Revenue TTM)
Gross Margin QoQ = 26.97% (prev 26.97%)
Tobins Q-Ratio = 1.68 (Enterprise Value 4.06b / Total Assets 2.42b)
Interest Expense / Debt = 1.18% (Interest Expense 10.9m / Debt 925.2m)
Taxrate = 19.29% (40.9m / 211.8m)
NOPAT = 170.2m (EBIT 210.9m * (1 - 19.29%))
Current Ratio = 3.45 (Total Current Assets 1.22b / Total Current Liabilities 353.1m)
Debt / Equity = 0.93 (Debt 925.2m / totalStockholderEquity, last quarter 994.7m)
Debt / EBITDA = 2.62 (Net Debt 820.0m / EBITDA 313.2m)
Debt / FCF = -44.96 (negative FCF - burning cash) (Net Debt 820.0m / FCF TTM -18.2m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 171.3m / Total Assets 2.42b)
RoE = 16.61% (Net Income TTM 171.3m / Total Stockholder Equity 1.03b)
RoCE = 14.99% (EBIT 210.9m / Capital Employed (Equity 1.03b + L.T.Debt 375.2m))
RoIC = 7.75% (NOPAT 170.2m / Invested Capital 2.20b)
WACC = 6.30% (E(3.24b)/V(4.16b) * Re(7.83%) + D(925.2m)/V(4.16b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.92 | Cagr: 0.47%
[DCF] Fair Price = unknown (Cash Flow -18.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.96 | Revenue CAGR: 2.12% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.13 | Chg30d=+1.92% | Revisions=+40% | GrowthEPS=+11.9% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=4.66 | Chg30d=+0.36% | Revisions=+40% | GrowthEPS=+13.0% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: +57% (up=4, down=0)